Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2017

01.06.2017 | original report

Distinct computed tomography features of non-small-cell lung cancer in a European population with EML4-ALK translocation

verfasst von: MD, M.B.A. Ullrich G. Mueller-Lisse, MD Hanna A. Zimmermann, Carolina Reiners, MD Simone Reu, MD Maximilian F. Reiser, MD Rudolf M. Huber, MD Amanda Tufman

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Treatment of advanced EML4-ALK-translocation-positive non-small-cell lung cancer (NSCLC) with an ALK tyrosine kinase inhibitor (TKI) is now standard of care. Since EML4-ALK gene fusion is rare in NSCLC and testing depletes both tissue samples and health care funds, deciding who to screen is critical. CT features associated with EML4-ALK-positive cases may help prioritize individual patients for ALK testing in settings where biopsy size or health care factors make ubiquitous testing difficult.

Methods

We used well-described computed tomography (CT) lung tumor features to distinguish EML4-ALK-translocation-positive from ALK-negative European patients with advanced NSCLC. CT scans were evaluated for lung tumor location (either central or peripheral versus combined), growth pattern (focal versus diffuse), array (single versus multiple lesions), delineation (infiltrative versus circumscribed), composition (solid only versus nonsolid parts), site-specific blood vessel appearance (normal versus altered), and air inclusions (present versus absent). Two-tailed statistical tests (Fisher exact/Student-T) were used to compare ALK-positive and ALK-negative tumors. The analyses took potential confounders into account including patient age, gender, previous NSCLC therapy, UICC stage, and smoking status.

Results

Ten of 39 adult European Caucasian patients (age 57 ± 10 years, 17 female) were ALK positive. Diffuse tumor growth (ALK positive 9, ALK negative 7/5, p < 0.0005/p < 0.0001, agreement 95%), multiple lung lesion arrays (ALK positive 9, ALK negative 6, p < 0.0002, agreement 82%), and combined central/peripheral tumor location (ALK positive 9, ALK negative 12/7, p < 0.01/p < 0.0005, agreement 82%) each were associated with ALK-positive cases.

Conclusions

Diffuse tumor growth, multiple lung lesion arrays, and combined central/peripheral tumor location are CT features that may prove useful in prioritizing NSCLC samples for ALK testing in this setting.
Literatur
1.
2.
Zurück zum Zitat Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. CrossRefPubMed Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. CrossRefPubMed
3.
7.
Zurück zum Zitat Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53. CrossRefPubMedPubMedCentral Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53. CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889–97. CrossRefPubMed Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889–97. CrossRefPubMed
10.
Zurück zum Zitat Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol. 2013;8:823–59. CrossRefPubMedPubMedCentral Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol. 2013;8:823–59. CrossRefPubMedPubMedCentral
11.
12.
Zurück zum Zitat Tufman AL, Edelmann M, Gamarra F, et al. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation. J Thorac Oncol. 2014;9:109–13. CrossRefPubMed Tufman AL, Edelmann M, Gamarra F, et al. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation. J Thorac Oncol. 2014;9:109–13. CrossRefPubMed
13.
Zurück zum Zitat Fukui T, Yatabe Y, Kobayashi Y, et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer. 2012;77:319–25. CrossRefPubMed Fukui T, Yatabe Y, Kobayashi Y, et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer. 2012;77:319–25. CrossRefPubMed
14.
Zurück zum Zitat Patsios D, Roberts HC, Paul NS, et al. Pictorial review of the many faces of bronchioloalveolar cell carcinoma. Br J Radiol. 2007;80:1015–23. CrossRefPubMed Patsios D, Roberts HC, Paul NS, et al. Pictorial review of the many faces of bronchioloalveolar cell carcinoma. Br J Radiol. 2007;80:1015–23. CrossRefPubMed
15.
Zurück zum Zitat Hulley SE, Cummings SR. Designing clinical research. Baltimore: Williams & Wilkins; 1988. Hulley SE, Cummings SR. Designing clinical research. Baltimore: Williams & Wilkins; 1988.
16.
Zurück zum Zitat Glantz SA. Primer of biostatistics, 4th ed. New York, St. Louis, San Francisco: McGraw-Hill Health Professions Division; 1997. Glantz SA. Primer of biostatistics, 4th ed. New York, St. Louis, San Francisco: McGraw-Hill Health Professions Division; 1997.
17.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74. CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74. CrossRefPubMed
18.
Zurück zum Zitat Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004–12. CrossRefPubMedPubMedCentral Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004–12. CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Qi M, Li Y, Liu J, et al. Morphologic features of carcinomas with recurrent gene fusions. Adv Anat Pathol. 2012;19:417–24. CrossRefPubMed Qi M, Li Y, Liu J, et al. Morphologic features of carcinomas with recurrent gene fusions. Adv Anat Pathol. 2012;19:417–24. CrossRefPubMed
20.
Zurück zum Zitat Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461:245–57. CrossRefPubMedPubMedCentral Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461:245–57. CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Martinez P, Hernández-Losa J, Montero MÁ, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLOS ONE. 2013;8:e52261. CrossRefPubMedPubMedCentral Martinez P, Hernández-Losa J, Montero MÁ, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLOS ONE. 2013;8:e52261. CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Li Y, Li Y, Yang T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLOS ONE. 2013;8:e52093. CrossRefPubMedPubMedCentral Li Y, Li Y, Yang T, et al. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLOS ONE. 2013;8:e52093. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Halpenny DF, Riely G, Yu H, et al. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung Cancer. 2014;86(2):190–4. CrossRefPubMedPubMedCentral Halpenny DF, Riely G, Yu H, et al. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung Cancer. 2014;86(2):190–4. CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Park J, Yamaura H, Yatabe Y, et al. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med. 2014;3(1):118–23. CrossRefPubMed Park J, Yamaura H, Yatabe Y, et al. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med. 2014;3(1):118–23. CrossRefPubMed
25.
Zurück zum Zitat Choi CM, Kim MY, Hwang HJ, et al. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology. 2015;275(1):272. CrossRefPubMed Choi CM, Kim MY, Hwang HJ, et al. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology. 2015;275(1):272. CrossRefPubMed
26.
Zurück zum Zitat Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer. 2013;79:242–7. CrossRefPubMed Choi H, Paeng JC, Kim DW, et al. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer. 2013;79:242–7. CrossRefPubMed
27.
Zurück zum Zitat Ko SJ, Lee YJ, Park JS, et al. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. BMC Cancer. 2014;14:312. CrossRefPubMedPubMedCentral Ko SJ, Lee YJ, Park JS, et al. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. BMC Cancer. 2014;14:312. CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Kobayashi Y, Mitsudomi T, Sakao Y, Yatabe Y. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Ann Oncol. 2015;26:156–61. CrossRefPubMed Kobayashi Y, Mitsudomi T, Sakao Y, Yatabe Y. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. Ann Oncol. 2015;26:156–61. CrossRefPubMed
29.
Zurück zum Zitat Yamamoto S, Korn RL, Oklu R, et al. ALK molecular phenotype in non–small cell lung cancer: CT radiogenomic characterization. Radiology. 2014;272:2. CrossRef Yamamoto S, Korn RL, Oklu R, et al. ALK molecular phenotype in non–small cell lung cancer: CT radiogenomic characterization. Radiology. 2014;272:2. CrossRef
30.
Zurück zum Zitat Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, et al. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLOS ONE. 2013;8(10):e76999. doi: 10.​1371/​journal.​pone.​0076999. CrossRefPubMedPubMedCentral Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, et al. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLOS ONE. 2013;8(10):e76999. doi: 10.​1371/​journal.​pone.​0076999. CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216–23. doi: 10.​1158/​1078-0432.​CCR-09-0802. CrossRefPubMedPubMedCentral Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216–23. doi: 10.​1158/​1078-0432.​CCR-09-0802. CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Novello A, Barlesi F, Califano R, Cufer T, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v1–v27. CrossRefPubMed Novello A, Barlesi F, Califano R, Cufer T, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v1–v27. CrossRefPubMed
34.
Zurück zum Zitat Proietti A, Ali G, Pelliccioni S, et al. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer. Cancer Cytopathol. 2014;122(6):61. CrossRef Proietti A, Ali G, Pelliccioni S, et al. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer. Cancer Cytopathol. 2014;122(6):61. CrossRef
35.
Zurück zum Zitat Kerr KM, MacKenzie SJ, Ramasami S, et al. Expression of fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma. J Pathol. 2004;203(2):638–44. CrossRefPubMed Kerr KM, MacKenzie SJ, Ramasami S, et al. Expression of fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma. J Pathol. 2004;203(2):638–44. CrossRefPubMed
36.
Zurück zum Zitat Grotheyl A, Heistermann P, Philippou S, Voigtmann R. Serum levels of soluble intercellular adhesion molecule-I (ICAMmI, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-I and tumour stage. Br J Cancer. 1998;77(5):801–7. CrossRef Grotheyl A, Heistermann P, Philippou S, Voigtmann R. Serum levels of soluble intercellular adhesion molecule-I (ICAMmI, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-I and tumour stage. Br J Cancer. 1998;77(5):801–7. CrossRef
Metadaten
Titel
Distinct computed tomography features of non-small-cell lung cancer in a European population with EML4-ALK translocation
verfasst von
MD, M.B.A. Ullrich G. Mueller-Lisse
MD Hanna A. Zimmermann
Carolina Reiners
MD Simone Reu
MD Maximilian F. Reiser
MD Rudolf M. Huber
MD Amanda Tufman
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0305-1

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe